To Assess Allisartan Isoproxil/Amlodipine in Patients With Essential Hypertension Uncontrolled With Amlodipine or Allisartan Isoproxil

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 499 participants.

Also called NCT06465264

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 499 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06465264
Other papers using this trial's data
  • Efficacy and Safety of Allisartan Isoproxil/Amlodipine in Patients With Essential Hypertension Uncontrolled by Amlodipine: A Phase III, Multicenter, Double-Blind, Parallel-Group, Randomized Controlled Trial Journal of clinical hypertension (Greenwich, Conn.), 2025-01 DOI, PubMed 39821945, PMC11771783 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06465264. Randomized; quadruple masking; primary purpose treatment. Start 2021-04-29 (actual); primary completion 2022-08-16 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
To Assess Allisartan Isoproxil/Amlodipine in Patients With Essential Hypertension Uncontrolled With Amlodipine or Allisartan Isoproxil
Condition
Essential Hypertension
Intervention (Drug)
Allisartan Isoproxil/Amlodipine group 1
Intervention (Drug)
Amlodipine group 1
Intervention (Drug)
Allisartan Isoproxil/Amlodipine group 2
Intervention (Drug)
Allisartan Isoproxil group 2
Lead sponsor
Shenzhen Salubris Pharmaceuticals Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct06465264
Content hash
d8236e801945109b2c5ac1da9c30f9786d75a5a853c7d8181adf579140273517